
    
      PRIMARY OBJECTIVES:

      I. To evaluate non-relapse mortality (NRM) up to day +100.

      SECONDARY OBJECTIVES:

      I. To evaluate non-relapse mortality (NRM) up to day +365. II. To evaluate the incidence of
      acute graft versus host disease (GVHD) and chronic GVHD up to day +365 post-transplant.

      III. To evaluate the overall survival and disease free survival up to 1 year. IV. To evaluate
      clinical response and molecular response (complete response and partial response) up to 1
      year.

      OUTLINE:

      Patients receive busulfan intravenously (IV) over 2 hours and fludarabine IV over 30 minutes
      on days -5 to -2. Patients undergo hematopoietic cell transplantation (HSCT) on day 0.
      Patients then receive cyclophosphamide IV over 60 minutes on days 3 and 4.

      After completion of study treatment, patients are followed up for 1 year.
    
  